News Focus
News Focus
Followers 67
Posts 2907
Boards Moderated 0
Alias Born 04/22/2022

Re: HyGro post# 765877

Monday, 05/05/2025 12:09:34 AM

Monday, May 05, 2025 12:09:34 AM

Post# of 822657
Gro,

Thanks for reposting your keen insights 😶

It sounds like you’re spreading rumors and disinformation. I believe you’re referring to Gilead’s Yescarta and your ‘facts’ are a little mixed up…

“As of early 2023, NICE has approved Yescarta (axicabtagene ciloleucel) for routine use in the NHS. After a series of reviews and negotiations, NICE endorsed Yescarta for adults with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL). The approval was based on the evidence of its effectiveness in prolonging survival compared to existing therapies.

This approval marked a shift from earlier hesitations due to concerns about high costs and uncertainty about long-term benefits. The conditional use through the Cancer Drugs Fund helped collect additional evidence, leading to the final NICE endorsement.”


https://pmlive.com/pharma_news/gileads_car-t_cell_therapy_recommended_by_nice_for_lymphoma_1485970/





NICE DCVax-L
Bullish
Bullish

Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News